Inari Medical Inc., an Irvine-based device maker of products to treat patients suffering from blood clots and other diseases affecting veins, reported third-quarter earnings that outpaced expectations.
The company (Nasdaq: NARI) reported net revenue of $38.7 million, above the consensus estimate of $26.5 million. Quarterly basic earnings per share were 12 cents, up from consensus estimates of 4 cents.
Inari cited hospital customers and physicians, who have “adapted and established a constructive operating environment for patient treatments,” as a driver of growth.
The company, which plans a major expansion of its Irvine headquarters, saw its shares fall 1.2% to $74.00 apiece in after-hours trading.
